Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | ALPI | P09923 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799844 | 0.91 | GAA (0.35) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL535602 | 0.91 | GAA (0.35) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL15728332 | 0.90 | GAA (0.32) | GAAHTTNPSR1MAPTALDH1A1 | |
| SCHEMBL30171015 | 0.85 | EDNRA (0.37) | GAANR1I2POLBMAPTTP53 | |
| SCHEMBL6640127 | 0.85 | EDNRA (0.37) | GAANR1I2POLBMAPTTP53 | |
| SCHEMBL4773317 | 0.84 | MAPT (0.36) | NR1I2POLBMAPTTP53ALDH1A1 | |
| SCHEMBL4773487 | 0.82 | EDNRB (0.35) | MAPTTP53 | |
| SCHEMBL30171191 | 0.82 | EDNRB (0.31) | — | |
| SCHEMBL4774297 | 0.82 | MAPT (0.34) | NR1I2MAPTTP53ALDH1A1KMT2A | |
| SCHEMBL29001508 | 0.82 | EDNRB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3222277-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY | LIGAND PHARM INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | LIGAND PHARMACEUTICALS INC. | 2018-12-06 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-12-14 | — | — | US | disclosed |
| EP-3222277-A1 | A DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONISTS TO TREATGLOMERULOSCLEROSIS | Ligand Pharmaceuticals Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9662312-B2 | Method for treating glomerulosclerosis | LIGAND PHARMACEUTICALS INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2732818-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS | LIGAND PHARM INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20150164865-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-06-18 | — | — | US | disclosed |
| US-20140142149-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | LIGAND PHARMACEUTICALS INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-1094816-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0996618-A1 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0996618-A4 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2000-05-03 | — | — | EP | disclosed |
| US-6043265-A | TREATING HYPERTENSION, PULMONARY HYPERTENSION, BENIGN PROSTATIC HYPERTROPHY, MIGRAINE, UROGENITAL DISORDERS, ENDOTOXEMIA, ISCHEMIA, ATHEROSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-28 | — | — | US | disclosed |
| WO-2000001389-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998033780-A1 | ENDOTHELIN ANTAGONISTS: N-[[2'-[ [(4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) [1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'-[(3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL)[1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142149-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | AGTR2, EDNRB, EDNRA | GAA 2626/4885NR1I2 523/4885HTT 3065/4885 |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | AGTR2, AGTR1, EDNRA | GAA 922/4885NR1I2 303/4885HTT 2136/4885 |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | REN, AGTR2, AGTR1 | GAA 131/4885NR1I2 564/4885HTT 3464/4885 |
| US-20150164865-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | AGTR2, EDNRB, EDNRA | GAA 2626/4885NR1I2 523/4885HTT 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.